Viking Therapeutics, Inc. (NAS: VKTX) Stock Analysis & Fundamentals

VKTXViking Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · vikingtherapeutics.com

36.37USD-3.81%Mkt Cap: 4.22B $P/E: —1d ago

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue an…

Headline	Source	Time
Yesterday
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know Viking Therapeutics, Inc. (VKTX) reached $36.37 at the closing of the latest trading day, reflecting a -3.81% change compared to its last close.	Zacks	18h
This GLP-1 Stock Could Double by 2030. Here's Why Investors need to ask tough questions before initiating a position in this biotech company.	Motley Fool	19h
This week
Here Is Why Viking Therapeutics (VKTX) is Amongst The Most Affordable Biotech Stocks to Buy Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 affordable biotech stocks to buy right now. On June 24, Viking Therapeutics Inc. (NASDAQ:VKTX) disclosed the launch of a Phase 1 Single Ascending Dose (SAD) medical study of VK3019. VK3019 is an experimental Dual Amylin and Calcitonin Receptor Agonist (DACRA), being developed as a possible weight […]	Insider Monkey	Jul 15
Older
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know	Zacks	Jul 10
Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With STEP UP Data	Simply Wall St.	Jul 9
3 High Growth GLP-1 Biotech Winners to Buy in July	24/7 Wall St.	Jul 9
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today	Zacks	Jul 8
Viking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year Run	Simply Wall St.	Jul 8
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal	Simply Wall St.	Jul 8
Viking Therapeutics (VKTX) Could Be 120% Undervalued On Obesity Pipeline Progress	Simply Wall St.	Jul 8
Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's Next	Simply Wall St.	Jul 8
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?	Stocktwits	Jul 8
Eli Lilly's Market Cap Balloons Again On This IPO's Setback	Investor's Business Daily	Jul 7
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?	Motley Fool	Jul 7
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?	Motley Fool	Jul 6
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?	Motley Fool	Jul 6
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?	Motley Fool	Jul 5
Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying	Motley Fool	Jul 4
Here's Why Viking Therapeutics Stock Surged Higher in June	Motley Fool	Jul 3
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know	Zacks	Jul 1
Is Viking Therapeutics Stock Going to $100?	Motley Fool	Jul 1
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?	Zacks	Jun 29
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?	Zacks	Jun 29
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?	Motley Fool	Jun 26
Viking Therapeutics (VKTX) Starts First Human Obesity Trial For VK3019	Simply Wall St.	Jun 25
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know	Zacks	Jun 25
VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug	Zacks	Jun 25
VKTX Stock Eyes Best Week In 2 Years: Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play	Stocktwits	Jun 25
VKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019	Stocktwits	Jun 24
Viking Therapeutics (VKTX) Soars Higher — Medicare Could Hold The Answer	Insider Monkey	Jun 24
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation	Stocktwits	Jun 23
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?	Motley Fool	Jun 23
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal	24/7 Wall St.	Jun 23
Is Viking Therapeutics Stock a No-Brainer Buy Below $35?	Motley Fool	Jun 23
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk	Motley Fool	Jun 23
Set It and Forget It: 2 Consumer Stocks to Hold for the Next 20 Years	Motley Fool	Jun 22
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know	Zacks	Jun 17
Viking Therapeutics (VKTX) Offers Potential With VK2735 Market Opportunity	Insider Monkey	Jun 17
Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation	Simply Wall St.	Jun 12
Is Viking Therapeutics Stock Going to $100?	Motley Fool	Jun 12
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know	Zacks	Jun 10
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%	Motley Fool	Jun 10
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider	Zacks	Jun 4
Should Viking’s VK2735 Obesity Program Advancements Require Action From Viking Therapeutics (VKTX) Investors?	Simply Wall St.	Jun 3
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock	Motley Fool	Jun 3
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside	Stocktwits	Jun 2
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down	Motley Fool	Jun 2
Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?	Zacks	May 29
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider	Zacks	May 28
If Viking Therapeutics Is Acquired, Here’s Who Wins	24/7 Wall St.	May 26

Industry Peers